This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Tony Pelz

Contributor to TheStreet

Tony Pelz was a trader on a major European bank's proprietary trading desk, responsible for a portfolio with limits of more than $200 million. Prior to proprietary trading, Pelz worked with several global investment banks in roles ranging from corporate finance, M&A to credit and business development. He is author of The Biotech Trader Handbook, 2nd Edition, co-founder of the small-cap biotech research and trading site Chimera Research Group and operator of Pelz currently resides in Denver, Colorado where he trades for his own account.

Tony Pelz
By This Author:
« Back
Page 1 of 2

Options Trade Into Ziopharm's Sarcoma Drug Study Results

By Tony Pelz

Options expert Tony Pelz says options are the best way to trade Ziopharma's looming palifosamide data.

11:00AM 02/26/13

Dynavax Options Trade for Heplisav FDA Approval Decision

By Tony Pelz

Options expert Tony Pelz offers investors a way to use options to trade Dynavax's upcoming FDA decision.

08:30AM 02/12/13

Alexza Pharma: Premium Selling Options Strategy

By Tony Pelz

A new options trade for Alexza going into an FDA drug approval decision.

11:27AM 12/12/12

Amicus: Bullish Options Trade Into Clinical Trial Catalysts

By Tony Pelz

Contributor Tony Pelz offers an options trade for those who believe Amicus shares are going higher.

09:05AM 12/04/12

Dynavax: Speculative Upside Options Trade

By Tony Pelz

How to use options to play a possible run-up in Dynavax prior to the FDA's approval decision.

07:31AM 11/20/12

Exelixis: New Drug Approval Options Trade

By Tony Pelz

Options wizard Tony Pelz suggests another way to trade Exelixis's FDA drug approval decision.

08:00AM 11/06/12

Eli Lilly: Bearish Options Trade

By Tony Pelz

Tony Pelz offers a short-term options trade to take advantage of end-of-year selling in Eli Lilly.

10:01AM 11/01/12

Ziopharm: Options Trade for Phase III Data

By Tony Pelz

How to play the high-risk release of results from Ziopharm's phase III study.

08:30AM 10/22/12

How to Hedge Profits in Sarepta Therapeutics

By Tony Pelz

Options guru Tony Pelz offers options trades for those who want to protect their Sarepta profits.

09:00AM 10/15/12

NPS Pharma: Bullish Options Trade Into the Gattex FDA Panel

By Tony Pelz

Biotech options expert Tony Pelz recommends a bullish options trade for the Oct. 16 Gattex FDA panel.

08:00AM 10/08/12

« Back
Page 1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV


DOW 17,191.37 -195.84 -1.13%
S&P 500 2,002.16 -27.39 -1.35%
NASDAQ 4,637.9940 -43.5030 -0.93%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs